欧盟委员会批准Kisunla用于确诊淀粉样蛋白病理的阿尔茨海默病患者-动脉网

European Commission Approves Kisunla for Alzheimer’s Patients with Confirmed Amyloid Pathology

GeneOnline 等信源发布 2025-09-26 20:16



可切换为仅中文







by Mark Chiang

由马克·蒋

Share To

分享到

The European Commission has granted approval for Kisunla, a treatment developed by Eli Lilly, to address Alzheimer’s disease in specific patient groups. The authorization applies to individuals with confirmed amyloid pathology who are either apolipoprotein E (ApoE4) heterozygotes or non-carriers. Kisunla is administered as a monthly infusion and is already available in several regions..

欧盟委员会已批准礼来公司开发的Kisunla用于治疗特定患者群体的阿尔茨海默病。该授权适用于经确认存在淀粉样蛋白病理且为载脂蛋白E（ApoE4）杂合子或非携带者的个体。Kisunla以每月输注的方式给药，已在多个地区上市。

This decision marks a significant regulatory milestone for the treatment of Alzheimer’s disease within the European Union. By targeting patients with amyloid pathology, Kisunla aims to address one of the key biological markers associated with the progression of Alzheimer’s. The approval follows extensive clinical evaluations and aligns with ongoing efforts to expand therapeutic options for neurodegenerative conditions..

这一决定标志着欧盟阿尔茨海默病治疗领域的一项重要监管里程碑。通过针对具有淀粉样蛋白病理的患者，Kisunla 旨在解决与阿尔茨海默病进展相关的关键生物标志物之一。该批准经过了广泛的临床评估，并与扩大神经退行性疾病治疗选择的持续努力相一致。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如果有任何建议和反馈，请联系我们。

Date: Got it! Please provide the date you’d like me to format, and I’ll convert it for you.

日期：明白了！请提供您想要格式化的日期，我会为您转换。